Esomeprazole
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Gastrointestinal Disease
Conditions
Gastrointestinal Disease, Signs and Symptoms, Digestive, Dyspepsia
Trial Timeline
Dec 1, 2002 → Jan 1, 2005
NCT ID
NCT00251914About Esomeprazole
Esomeprazole is a phase 3 stage product being developed by AstraZeneca for Gastrointestinal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00251914. Target conditions include Gastrointestinal Disease, Signs and Symptoms, Digestive, Dyspepsia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01370538 | Phase 3 | Completed |
| NCT01370525 | Phase 3 | Completed |
| NCT00474019 | Phase 1 | Completed |
| NCT00427635 | Phase 3 | Completed |
| NCT00384592 | Approved | Completed |
| NCT00318968 | Approved | Completed |
| NCT00608712 | Approved | Completed |
| NCT00251979 | Phase 3 | Completed |
| NCT00392002 | Approved | Completed |
| NCT00242736 | Approved | Completed |
| NCT00291746 | Approved | Completed |
| NCT00206440 | Phase 3 | Terminated |
| NCT00243724 | Phase 3 | Completed |
| NCT00524251 | Pre-clinical | Completed |
| NCT00251966 | Phase 3 | Completed |
| NCT00251901 | Phase 3 | Completed |
| NCT00120315 | Approved | Completed |
| NCT00574925 | Approved | Completed |
| NCT00222131 | Phase 2 | Completed |
| NCT00318084 | Approved | Completed |
Competing Products
20 competing products in Gastrointestinal Disease